These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 8293758

  • 1. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R.
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [Abstract] [Full Text] [Related]

  • 2. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB.
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [Abstract] [Full Text] [Related]

  • 3. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC, Morton BC, Green MS, Tang AS.
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [Abstract] [Full Text] [Related]

  • 4. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN, Wadhani N.
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [Abstract] [Full Text] [Related]

  • 5. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization.
    Roden DM.
    Eur Heart J; 1993 Nov; 14 Suppl H():56-61. PubMed ID: 8293755
    [Abstract] [Full Text] [Related]

  • 6. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA, Kluger J, White CM.
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [Abstract] [Full Text] [Related]

  • 7. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L, Breithardt G, Haverkamp W.
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [Abstract] [Full Text] [Related]

  • 8. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs.
    Cubeddu LX.
    Am J Ther; 2003 Jan; 10(6):452-7. PubMed ID: 14624285
    [Abstract] [Full Text] [Related]

  • 9. Drug-induced torsade de pointes.
    Raehl CL, Patel AK, LeRoy M.
    Clin Pharm; 1985 Jan; 4(6):675-90. PubMed ID: 2416504
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
    Milberg P, Ramtin S, Mönnig G, Osada N, Wasmer K, Breithardt G, Haverkamp W, Eckardt L.
    J Cardiovasc Pharmacol; 2004 Sep; 44(3):278-86. PubMed ID: 15475823
    [Abstract] [Full Text] [Related]

  • 11. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G.
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [Abstract] [Full Text] [Related]

  • 12. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
    Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH.
    JAMA; 1993 Dec 01; 270(21):2590-7. PubMed ID: 8230644
    [Abstract] [Full Text] [Related]

  • 13. Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization.
    Milberg P, Frommeyer G, Uphaus T, Kaiser D, Osada N, Breithardt G, Eckardt L.
    J Cardiovasc Pharmacol; 2012 Jan 01; 59(1):92-100. PubMed ID: 21964157
    [Abstract] [Full Text] [Related]

  • 14. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S, Rao ML, Schröder R, Lüderitz B, Bauriedel G.
    Dtsch Med Wochenschr; 2001 Dec 07; 126(49):1396-400. PubMed ID: 11740632
    [Abstract] [Full Text] [Related]

  • 15. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
    Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G.
    Curr Clin Pharmacol; 2017 Dec 07; 12(4):210-222. PubMed ID: 29473523
    [Abstract] [Full Text] [Related]

  • 16. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P, Hreiche R, Turgeon J.
    Can J Cardiol; 2005 Aug 07; 21(10):857-64. PubMed ID: 16107909
    [Abstract] [Full Text] [Related]

  • 17. Ibutilide-induced long QT syndrome and torsade de pointes.
    Gowda RM, Punukollu G, Khan IA, Patlola RR, Tejani FH, Cosme-Thormann BF, Vasavada BC, Sacchi TJ.
    Am J Ther; 2002 Aug 07; 9(6):527-9. PubMed ID: 12424513
    [Abstract] [Full Text] [Related]

  • 18. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
    Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF.
    J Cardiovasc Pharmacol; 2001 May 07; 37(5):607-18. PubMed ID: 11336111
    [Abstract] [Full Text] [Related]

  • 19. [Amiodarone therapy after sotalol-induced torsade de pointes: prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects].
    van de Loo A, Klingenheben T, Hohnloser SH.
    Z Kardiol; 1994 Dec 07; 83(12):887-90. PubMed ID: 7846927
    [Abstract] [Full Text] [Related]

  • 20. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias.
    Van Opstal JM, Leunissen JD, Wellens HJ, Vos MA.
    Eur J Pharmacol; 2001 Jan 19; 412(1):67-76. PubMed ID: 11166738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.